Literature DB >> 10373069

Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant.

C Selleri1, J P Maciejewski, G De Rosa, A Raiola, A M Risitano, M Picardi, L Pezzullo, L Luciano, P Ricci, G Varriale, P Della Cioppa, L Del Vecchio, B Rotoli.   

Abstract

We investigated bone marrow (BM) and circulating (PB) hematopoietic progenitor cells in 37 normal donors and in 25 patients 1 to 8 years after successful allogeneic bone marrow transplant. At the time of testing, transplanted patients had normal blood counts and bone marrow cellularity. By flow cytometry, BM CD34+ cells were found to be three- to four-fold decreased in transplanted patients compared to normal donors, while the number of PB CD34+ cells was the same as in normal donors. Using a methylcellulose colony assay, primary BM colony-forming cells (CFU-GM) were decreased 2.1-fold, whereas PB CFU-GM were only marginally decreased. In a long-term culture initiating cell (LTC-IC) assay, an eight-fold decrease of early progenitor cells was observed in the marrow of transplanted patients compared to normal donors, and a five-fold decrease was documented in peripheral blood. We found that the BM LTC-IC cell number correlated with concurrently determined BM CD34+ cells and committed progenitor cell number (measured as CFU-GM) and with PB LTC-IC number, but not with PB CFU-GM and CD34+ cells. We conclude that marrow and circulating early stem cell compartments, as measured by the LTC-IC assay, are greatly and permanently depressed following bone marrow transplant. The correlation between BM and PB LTC-IC indicates that the enumeration of circulating LTC-IC can be used as a measure of the stem cell compartment in the bone marrow after transplant. It seems that the deficiency of the most immature progenitor cells persists forever after successful bone marrow transplant; this means that a complete hematopoietic reconstitution can be sustained by a reduced stem cell pool.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373069     DOI: 10.1038/sj.bmt.1701759

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.

Authors:  L Tauchmanovà; C Selleri; M Esposito; C Di Somma; F Orio; G Bifulco; S Palomba; G Lombardi; B Rotoli; A Colao
Journal:  Osteoporos Int       Date:  2003-09-30       Impact factor: 4.507

Review 2.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

3.  Nfix Promotes Survival of Immature Hematopoietic Cells via Regulation of c-Mpl.

Authors:  Trent Hall; Megan Walker; Miguel Ganuza; Per Holmfeldt; Marie Bordas; Guolian Kang; Wenjian Bi; Lance E Palmer; David Finkelstein; Shannon McKinney-Freeman
Journal:  Stem Cells       Date:  2018-02-27       Impact factor: 6.277

4.  Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources.

Authors:  J Dmytrus; S Matthes-Martin; H Pichler; N Worel; R Geyeregger; N Frank; C Frech; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

5.  Regulated expression of CXCR4 constitutive active mutants revealed the up-modulated chemotaxis and up-regulation of genes crucial for CXCR4 mediated homing and engraftment of hematopoietic stem/progenitor cells.

Authors:  M Sharma; F Afrin; Rp Tripathi; G Gangenahalli
Journal:  J Stem Cells Regen Med       Date:  2013-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.